Expression and prognostic characteristics of m5C regulators in low‐grade glioma

Glioma is the most common intracranial malignant tumour. A clear diagnosis and molecular targeted therapy are of great significance for improving the survival time and quality of life of patients with low‐grade glioma. 5‐methylcytosine methylation is one of the ways of RNA modification, but there are limited studies on the role of m5C methylation of low‐grade glioma. Single‐nucleotide variant, RNA expression matrix and corresponding clinical data of low‐grade glioma came from public database. The single‐nucleotide variant and expression of m5C regulators were estimated. A prognostic model based on m5C regulators was constructed by Cox regression. Potential functions of these molecules were assessed by gene set enrichment analysis. DNMT3A mutation was the most frequent among the m5C regulators in low‐grade glioma. NSUN3, TET2, TRDMT1, ALYREF, DNMT3B, DNMT1, NOP2 and NSUN2 were up‐regulated. One prognostic model was constructed which had a strong predictive power for the overall survival of low‐grade glioma. We studied the expression and prognostic characteristics of m5C regulators in low‐grade glioma, supplied biomarkers for the diagnosis and prognosis and provided the foundation for the study of the pathogenesis of low‐grade glioma.